Description: Surface Oncology is a clinical-stage immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47 and CD73. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response, alone or in combination with other therapies. The company has a pipeline of immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.
Home Page: www.surfaceoncology.com
SURF Technical Analysis
50 Hampshire Street
Cambridge,
MA
02139
United States
Phone:
617 714 4096
Officers
| Name | Title |
|---|---|
| Dr. Robert W. Ross M.D. | Pres, CEO & Director |
| Dr. Vito J. Palombella Ph.D. | Chief Scientific Officer |
| Dr. Alison O'Neill M.D. | Chief Medical Officer |
| Ms. Jessica Fees CPA | CFO & Treasurer |
| Ms. Chandra Adams J.D. | VP of Legal & Intellectual Property, Dep. Gen. Counsel and Corp. Sec. |
| Ms. Lisa McGrath | Chief People Officer |
| Mr. Henry C. Rath | Chief Bus. Officer |
| Ms. Shannon Rourke Devens | Sr. VP of Devel. Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4724 |
| Price-to-Sales TTM: | 1.6001 |
| IPO Date: | 2018-04-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 67 |